Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tildrakizumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Almirall To Present New Psoriasis Atopic Dermatitis Data
    Almirall To Present New Psoriasis Atopic Dermatitis Data

    23 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240923201861/en

    BUSINESSWIRE
    23 Sep 2024
    Share Share
    Sun Pharma's Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.
    Sun Pharma's Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.

    04 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761067

    FDA
    04 Apr 2024
    Share Share
    Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list
    Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list

    13 Dec 2023

    // ECONOMIC TIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-specialty-drug-tildrakizumab-makes-it-to-chinas-reimbursement-list/articleshow/105967100.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    ECONOMIC TIMES
    13 Dec 2023
    Share Share
    Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing
    Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing

    11 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231011690776/en

    BUSINESSWIRE
    11 Oct 2023
    Share Share
    Almirall: Ilumetri improved the wellbeing of patients with plaque psoriasis
    Almirall: Ilumetri improved the wellbeing of patients with plaque psoriasis

    07 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230707896992/en

    BUSINESSWIRE
    07 Jul 2023
    Share Share
    Sun Pharma gets China NMPA approval for ILUMETRI
    Sun Pharma gets China NMPA approval for ILUMETRI

    30 May 2023

    // EXPRESSPHARMA

    https://www.expresspharma.in/sun-pharma-gets-china-nmpa-approval-for-ilumetri-to-treat-moderate-to-severe-plaque-psoriasis/

    EXPRESSPHARMA
    30 May 2023
    Share Share